Giuseppe Curigliano Selected Research

sabatolimab

1/2021

Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Giuseppe Curigliano Research Topics

Disease

175	Neoplasms (Cancer) 06/2022 - 03/2003
157	Breast Neoplasms (Breast Cancer) 08/2022 - 09/2002
24	Triple Negative Breast Neoplasms 08/2022 - 01/2013
22	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 05/2002
16	Disease Progression 01/2022 - 05/2007
14	Neoplasm Metastasis (Metastasis) 01/2022 - 09/2002
10	Microsatellite Instability 01/2022 - 01/2017
10	COVID-19 01/2022 - 01/2020
10	Melanoma (Melanoma, Malignant) 01/2022 - 08/2013
10	Cardiotoxicity 09/2021 - 09/2010
8	Prostatic Neoplasms (Prostate Cancer) 02/2021 - 05/2007
7	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 04/2013
5	Lung Neoplasms (Lung Cancer) 03/2022 - 07/2003
5	Carcinoma (Carcinomatosis) 01/2022 - 03/2005
5	Heart Failure 01/2018 - 09/2010
4	Stomach Neoplasms (Stomach Cancer) 01/2022 - 09/2007
4	Brain Neoplasms (Brain Tumor) 01/2021 - 11/2017
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 02/2013
4	Pain (Aches) 01/2018 - 09/2007
3	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2022 - 09/2017
3	Hepatocellular Carcinoma (Hepatoma) 10/2021 - 01/2014
3	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2021 - 03/2020
3	Circulating Neoplastic Cells 01/2021 - 10/2010
3	Fatigue 01/2021 - 01/2018
3	Carcinogenesis 01/2019 - 12/2016
3	Venous Thromboembolism 01/2018 - 10/2005
2	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 12/2021

Drug/Important Bio-Agent (IBA)

37	Biomarkers (Surrogate Marker)IBA 06/2022 - 09/2007
26	Hormones (Hormone)IBA 04/2022 - 10/2004
24	Immune Checkpoint InhibitorsIBA 05/2022 - 03/2014
23	Trastuzumab (Herceptin)FDA Link 08/2022 - 01/2006
23	Pharmaceutical PreparationsIBA 03/2022 - 03/2003
21	Estrogen ReceptorsIBA 01/2022 - 10/2004
19	Biological ProductsIBA 01/2022 - 03/2004
15	VaccinesIBA 01/2022 - 09/2007
14	ErbB Receptors (EGF Receptor)IBA 11/2021 - 12/2004
13	Progesterone Receptors (Progesterone Receptor)IBA 01/2021 - 06/2004
12	human ERBB2 proteinIBA 01/2022 - 11/2013
12	AntigensIBA 01/2022 - 10/2009
11	Immunoconjugates (Immunoconjugate)IBA 05/2022 - 01/2019
10	Phenobarbital (Luminal)FDA Link 02/2020 - 10/2012
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2003
9	COVID-19 VaccinesIBA 01/2022 - 01/2021
9	AnthracyclinesIBA 11/2021 - 06/2015
8	Biosimilar PharmaceuticalsIBA 01/2021 - 09/2014
7	Cancer VaccinesIBA 01/2022 - 09/2007
7	Gefitinib (Iressa)FDA Link 01/2021 - 02/2005
7	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 03/2003
7	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 09/2004
6	AntibodiesIBA 01/2022 - 08/2013
6	Monoclonal AntibodiesIBA 01/2022 - 09/2010
6	Tyrosine Kinase InhibitorsIBA 11/2021 - 09/2010
6	Neoplasm Antigens (Tumor Antigens)IBA 11/2015 - 12/2007
5	atezolizumabIBA 09/2021 - 01/2019
5	palbociclibIBA 01/2021 - 01/2019
4	pembrolizumabIBA 08/2022 - 01/2019
4	pertuzumabIBA 08/2022 - 01/2018
4	Ado-Trastuzumab EmtansineIBA 01/2022 - 01/2018
4	LigandsIBA 01/2022 - 02/2015
4	NivolumabIBA 01/2022 - 01/2020
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 09/2012
4	AlpelisibIBA 11/2021 - 08/2018
4	ribociclibIBA 11/2021 - 05/2017
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 08/2021 - 01/2020
4	Capecitabine (Xeloda)FDA Link 01/2021 - 06/2015
4	Paclitaxel (Taxol)FDA LinkGeneric 03/2020 - 12/2006
3	B7-H1 AntigenIBA 02/2022 - 01/2019
3	taxaneIBA 01/2022 - 03/2005
3	trastuzumab deruxtecanIBA 01/2022 - 12/2021
3	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 10/2021 - 11/2015
3	Taxoids (Taxanes)IBA 09/2021 - 03/2005
3	IpilimumabIBA 09/2021 - 08/2013
3	tucatinibIBA 01/2021 - 01/2020
3	Bevacizumab (Avastin)FDA Link 01/2020 - 06/2015
3	Gemcitabine FDA Link 01/2020 - 09/2004
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 09/2019 - 01/2018
3	TOR Serine-Threonine KinasesIBA 09/2019 - 01/2018
3	Peptides (Polypeptides)IBA 04/2019 - 09/2007
3	CTLA-4 AntigenIBA 01/2019 - 11/2013
3	PlatinumIBA 01/2018 - 03/2005
3	Circulating Tumor DNAIBA 01/2017 - 06/2014
3	Methotrexate (Mexate)FDA LinkGeneric 01/2016 - 09/2002
3	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2009 - 05/2007
3	Androgen Antagonists (Antiandrogens)IBA 01/2009 - 05/2007
3	Fluorouracil (Carac)FDA LinkGeneric 09/2007 - 01/2006

Therapy/Procedure

92	Therapeutics 04/2022 - 06/2004
59	Drug Therapy (Chemotherapy) 08/2022 - 05/2002
34	Immunotherapy 08/2022 - 09/2007
13	Precision Medicine 07/2021 - 01/2014
12	Neoadjuvant Therapy 08/2022 - 01/2013
10	Radiotherapy 01/2021 - 03/2004
9	Adjuvant Chemotherapy 04/2022 - 01/2013
6	Catheters 10/2009 - 11/2002
5	Mastectomy (Mammectomy) 08/2017 - 03/2004
4	Aftercare (After-Treatment) 01/2022 - 12/2004
4	Mammaplasty (Breast Reconstruction) 10/2015 - 08/2011
3	Breast Implants (Breast Implant) 01/2021 - 03/2020
3	Biological Therapy 01/2020 - 01/2015
3	Induction Chemotherapy 08/2007 - 09/2004
2	Palliative Care (Palliative Therapy) 03/2022 - 01/2020